Binding proteins and methods of use thereof
AssigneeNGM Biopharmaceuticals, Inc.
InventorsWenyan Shen, Jie Tang, Yan Wang, Hugo Matern
Life of this patent
Estimating the term…
Abstract
The present disclosure provides binding proteins, such as antibodies, that bind to a GDNF Family Receptor Alpha Like (GFRAL) protein, including human GFRAL protein, and methods of their use.
Claims20
A method for treating cachexia, involuntary weight loss, sarcopenia, or muscle wasting in a human subject suffering from cancer associated with elevated levels of GDF15, the method comprising administering to the human subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to a GDNF Family Receptor Alpha-Like (GFRAL) protein, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL), and
- wherein the VH comprises a VH complementarity determining region (CDR) 1, a VH CDR2, and a VH CDR3 from the amino acid sequence of SEQ ID NO:3, and the VL comprises a VL CDR1, a VL CDR2, and a VL CDR3 from the amino acid sequence of SEQ ID NO:4.
A method for treating a GDF15-mediated cancer in a human subject, the method comprising administering to the human subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to a GDNF Family Receptor Alpha-Like (GFRAL) protein, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL),
- wherein the VH comprises a VH complementarity determining region (CDR) 1, a VH CDR2, and a VH CDR3 from the amino acid sequence of SEQ ID NO:3, and the VL comprises a VL CDR1, a VL CDR2, and a VL CDR3 from the amino acid sequence of SEQ ID NO:4,
- wherein the human subject has an elevated serum level of GDF 15;
- and
- wherein the GDF15-mediated cancer is prostate cancer.
Dependencies are inferred from the claim text.